All In Biotech

Free tool

FAERS Monitor: Linzess

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 202811 or its brand name (Linzess, Linaclotide). Reports on generic versions are filed under their own applications.

Reports

27,305

Serious

9,962

36% of reports

Hospitalization

4,080

Death reported

1,100

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea4,777
  • drug ineffective4,586
  • off label use3,406
  • constipation2,071
  • nausea1,522
  • fatigue1,213
  • abdominal distension1,188
  • abdominal pain1,089
  • headache1,073
  • pain991
  • abdominal pain upper969
  • dizziness879
  • inappropriate schedule of product administration787
  • fall743
  • flatulence721

Reports by year received

View as table
YearReports
20129
2013597
20141,295
20151,290
20162,129
20172,256
20182,579
20192,374
20202,225
20211,937
20221,882
20231,994
20242,049
20252,478
20262,211

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,026,854 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
flatulenceSignal7219.99.25,706
abdominal distensionSignal1,1888.98.48,218
constipationSignal2,0717.47.111,417
diarrhoeaSignal4,7775.75.619,122
abdominal pain upperSignal9693.63.41,860
abdominal painSignal1,0893.63.42,074
inappropriate schedule of product administrationSignal7873.43.11,318
off label useSignal3,4063.02.94,731
drug ineffectiveSignal4,5862.72.65,159
fall7431.71.6227
nausea1,5221.51.4247
dizziness8791.41.385
headache1,0731.31.285
pain9911.21.248
fatigue1,2131.21.142

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.